Kornimate/medical-research-clean huggingface dataset:
the effect of pentoxifylline on liver function tests in fatty liver disease

Conditions: Fatty Liver

Summary: this randomized double blind clinical trial was performed in patients with non-alcoholic fatty liver disease.they were randomly assigned to lifestyle modification alone or lifestyle modification plus pentoxifylline groups. liver function tests, metabolic profile and anthropometric measurements were checked at baseline and six months later.

this randomized double blind clinical trial was performed in patients with the evidence of fatty liver in ultrasonography. after excluding other causes, participants with persistent elevated serum aminotransferase levels were presumed to have nafld. those with nafld liver fat score greater than (-0.64) were enrolled. they were randomly assigned to lifestyle modification alone or lifestyle modification plus pentoxifylline groups. fasting serum glucose, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, triglyceride, cholesterol, high and low-density lipoprotein,homeostasis model assessment-insulin resistance(homa-ir), and anthropometric measurements (body mass index and waist circumference) were checked at baseline and six months later.

Eligibility criteria:
inclusion criteria: patients with persistent elevated aminotransferase levels and the evidence of fatty liver in ultrasonography, who were referred to a gastroenterology clinic. exclusion criteria: * alcohol use (more than 20 gram per day in men and 10 gram per day in women per day), * heart disease (ischemic or congestive), * hepatic disease (viral hepatitis, autoimmune hepatitis, wilson disease, hemochromatosis, liver mass lesion), * renal disease (serum creatinine concentration of \> 1.5 mg/dl), * any severe systemic co-morbidities, neoplasm, * using any hepatotoxic medication during the past 3 months, * pregnant or lactating women.

Keywords: pentoxifylline aminotransferase steatohepatitis
the effect of enzyme-containing mouth spray on oral health status and s.mutans levels in paediatric patients

Conditions: Gingivitis; Plaque Induced Gingivitis

Summary: an interventional study was done on evaluating the effect of enzyme-containing mouth spray on oral health status and s.mutans levels in paediatric patients attending hospital universiti sains malaysia ( husm ) , kelantan. this study compared the gingivitis score , plaque score and saliva bacteria count between the patients receiving a standard preventive advice alongside with normal saline mouth spray and those receiving standard preventive advice alongside with an enzyme containing mouth spray .

general objective to evaluate the effect of enzyme-containing mouth sprays on children's oral health compared to those receiving normal saline mouth spray with standard preventive advice after a 4-week follow-up. specific objectives 1. to compare the mean plaque score in children using enzyme-containing mouth sprays with standard preventive advice compared to children receiving normal saline mouth spray with standard preventive advice after a 4-week follow-up. 2. to compare the mean gingivitis score in children using enzyme-containing mouth sprays with standard preventive advice compared to children receiving normal saline mouth spray with standard preventive advice after a 4-week follow-up. 3. to compare the mean saliva bacterial count in children using enzyme-containing mouth sprays with standard preventive advice compared to children receiving receiving normal saline mouth spray with standard preventive advice after a 4-week follow-up.

Eligibility criteria:
inclusion criteria: * children of age group 4-7 exclusion criteria: * children with medical problems * children with special needs * uncooperative children ( level of cooperation would be measured using frankl's behavior scale) reviewer's comment : to list down frankl's classification and how we define uncooperative as per aapd 2022 , the frankl behavior rating scale is a frequently used behavior rating systems in both clinical dentistry and research. this scale indicates observed child's behaviors into four categories (1; definitely negative, 2; negative, 3; positive, 4; definitely positive) 1. _ _ definitely negative. refusal of treatment, forceful crying, fearfulness, or any other overt evidence of extreme negativism. 2. _ negative. reluctance to accept treatment, uncooperative, some evidence of negative attitude but not pronounced (sullen, withdrawn). 3. + positive. acceptance of treatmen, cautious behavior at times, willingness to comply with the dentist, at times with reservation, but patient follows the dentist's directions cooperatively. 4. ++ definitely positive. good rapport with the dentist, interest in the dental procedures, laughter and enjoyment
protecting young special risk females from cervical cancer through human papilloma virus (hpv) vaccination

Conditions: Cervical Cancer

Summary: a research project is currently being undertaken looking at human papilloma virus (hpv) vaccination in special risk groups. it aims to see if young women with a chronic illness respond well to the hpv vaccine or whether they may require additional doses to ensure protective immunity. the four valent hpv vaccine protects against hpv types 16 \& 18, cervical cancer and hpv types 6 \& 11, anogenital warts. the six special risk groups include: paediatric rheumatological disease inflammatory bowel disease acute lymphoblastic leukaemia solid organ transplant recipients (kidney and liver) chronic renal disease bone marrow transplants this immunity is measured by antibody levels of the hpv types, which requires a single blood test one month after the final dose of hpv vaccine. this is compared to healthy controls using antibody response to hpv vaccine. this will assess directly whether these special risk groups respond as well to the hpv vaccine.


Eligibility criteria:
inclusion criteria: * females aged 12-26 years * have been diagnosed by a specialist with one of the six chronic medical conditions described: 1. paediatric rheumatological disease 2. inflammatory bowel disease 3. acute lymphoblastic leukaemia 4. solid organ transplant recipients (kidney and liver) 5. chronic renal disease 6. bone marrow transplant exclusion criteria: * previous immunisation with hpv vaccine recognised contraindication to the receipt of the vaccine e.g. anaphylaxis

Keywords: juvenile idiopathic arthritis inflammatory bowel disease acute lymphoblastic leukemia chronic renal disease solid organ transplant
video-assisted thoracoscopic surgery - exparel study

Conditions: Pain, Postoperative

Summary: video-assisted thoracoscopic surgery (vats) greatly decreased the number and types of surgery that required open thoracotomy. initially it was thought that vats would lead to a reduction of respiratory problems and less acute pain in patients when compared to patients receiving an open thoracic surgery. however, for reasons not clearly understood, a large number of patients who undergo vats still experience moderate to severe post-surgical pain. physicians are still faced with the challenge of providing care that will manage both the respiratory issues as well as manage acute pain. the goal of this study is to find the most suitable regimen to effectively manage post-vats-related pain.

the "promise" was that video-assisted thoracoscopic surgery (vats) would be associated with less severe pulmonary impairment and less acute post-operative pain compared to open thoracotomy. however, vats can cause moderate to severe post-operative pain in a significant number of patients and the reason for this is not well understood. in addition it has been found that post-surgical pain can be a strong predictor for the development of chronic pain. inadequate control of acute pain not only causes serious discomfort and significant respiratory problems, but it may place this population of patients at greater risk of chronic pain and prescription opioid dependence. current protocols to manage and/or reduce vats associated pain include combining the use of regional anesthesia techniques with opioid and non-opioid analgesics. recent studies have investigated the efficacy of intercostal blocks using liposomal bupivacaine after thoracic surgery. however, these studies lacked an active comparator population of patients. the study is designed as a prospective randomized study evaluating intercostal blocks using liposomal bupivacaine. the control population of patients will be treated with a paravertebral block using plain bupivacaine.

Eligibility criteria:
inclusion criteria: * age over 18 years and less than 80 years * undergoing video-assisted thoracoscopic surgery (vats) procedure * bmi less than 40 exclusion criteria: * unable to provide informed consent * non-english speaking * pregnant * bmi greater than 40 * video-assisted thoracoscopic surgery pleurodesis subjects * patients with pre-existing chronic pain * opioid tolerance * pain syndromes including fibromyalgia, regional pain syndrome or post therapeutic neuralgia in a thoracic distribution * allergy to the study medication * patients with infectious disease * patients with impaired coagulation * severe hepatic disease * incarcerated

Keywords: video-assisted thoracoscopic surgery (vats) paravertebral blocks liposomal bupivacaine (exparel)
study of lipid mediators in chronic postoperative pain - licp

Conditions: Breast Cancer Female; Postoperative Pain

Summary: this interventional prospective study aims firstly to investigate variations in lipid levels in blood samples and their potential relationship with the duration and/or intensity of post-operative pain. secondly, it aims to investigate the activation of peripheral blood mononuclear cells and neutrophils in patient blood samples. the study will enrol women aged 18 years or older who have been newly diagnosed with primary invasive or non-invasive breast cancer requiring surgical removal of the tumour, with or without axillary surgery. the main objectives of the study are to assess whether there is an association between circulating levels of lipid mediators and chronicity (\> 3 months) of postoperative pain after breast cancer surgery. to assess whether circulating levels of lipid mediators can predict chronicity of postoperative pain in breast cancer surgery. to assess the existence of an association between resected tissue levels of lipid mediators and chronicity of postoperative pain in breast cancer surgery. to assess whether tissue levels of lipid mediators can predict chronicity of postoperative pain in breast cancer surgery.


Eligibility criteria:
inclusion criteria: * women older than 18 years * newly diagnosed primary invasive or non-invasive breast cancer, requiring surgical excision of the tumor, with or without axillary surgery * able to give informed consent exclusion criteria: * men * women aged less than 18 years * pregnant women * history of major psychiatric disorders * previous breast or axillary surgery, recurrent disease or detectable metastatic disease at the time of diagnosis * unable to give informed consent
transverse thoracic plane block, midpoint transverse process plane to pleura block and erector spinae plane block for analgesia in patients undergoing thoracoscopic sympathectomy

Conditions: Transverse Thoracic Plane Block; Midpoint Transverse Process Plane to Pleura Block; Erector Spinae Plane Block; Analgesia; Thoracoscopic Sympathectomy

Summary: this study compares the transversus thoracic muscle plane block (ttpb), midtransverse to pleura block (mtpb), and erector spinae plane block (espb) for postoperative analgesia in patients undergoing thoracoscopic sympathectomy.

thoracoscopic sympathectomy is a well-established procedure for the treatment of various hyperhidrosis disorders and certain vascular conditions, involving the division of sympathetic nerve fibers in the thoracic cavity. the erector spinae plane block (espb) is an interfascial regional anesthesia block for thoracic analgesia which can be performed by superficial or deep needle approach. the mid-transverse to pleura block (mtpb) was first described as a modified paravertebral block. transversus thoracic muscle plane block (ttpb) is a newly developed technique in which la is injected into the fascial plane between the transversus thoracic muscle and the internal intercostal muscles for blocking the anterior cutaneous branches of intercostal nerves from thoracic (th) 2 to th 6.

Eligibility criteria:
inclusion criteria: * age from 18 to 65 years. * both sexes. * american society of anesthesiology (asa) physical status i-ii. * scheduled for thoracoscopic sympathectomy exclusion criteria: * coagulopathy. * history of opiate abuse. * pre-existing chronic pain. * allergy to local anesthetics or analgesics. * infection at the site of injection. * mental or neurological disorders. * pregnancy
double-blind trial of mannitol cream to block the effect of capsaicin cream

Conditions: Pain

Summary: capsaicin is a trpv1 (transient receptor potential vanilloid 1) agonist, causing pain upon application. the investigators wish to determine whether mannitol blocks the effect of capsaicin application. as both cream bases are identical and mannitol addition is the only difference between the creams, if the mannitol cream is more effective in blocking the effect of capsaicin on the trpv1 (transient receptor potential vanilloid 1) receptor, the investigators will have established that mannitol down-regulates or blocks the trpv1 (transient receptor potential vanilloid 1) receptor.

capsaicin cream, which stimulates the trpv1 (transient receptor potential vanilloid 1) receptor, causing a burning sensation, will be applied to both halves of the upper lip until a burning sensation with 8/10 intensity on an nrs (visual analog scale) scale is experienced or five minutes have elapsed. following this, the capsaicin cream will be wiped off and 30% mannitol in vehicle cream ( isopropyl palmitate, caprylic capric triglyceride, propylene glycol, ceteareth 20, cetearyl alcohol, glyceryl stearate, polyethylene glycol 100 stearate, dimethicone, octyldodecanol, lecithin, ethylhexyl glycerin and phenoxy ethanol) will be applied to one half of the upper lip, and vehicle cream alone will be applied to the other half. cream assignment will be randomized and neither the subject nor the person applying the cream will know which half upper lip has which cream. every minute for 10 minutes, the heat sensation felt in each half upper lip will be measured, using a visual scale from 0 to 10. a repeated measures analysis of variance will compare the nrs (visual analog scale) scores from the 30% mannitol cream, to the nrs (visual analog scale)scores from the vehicle cream. significance will be accepted if p less than .05.

Eligibility criteria:
inclusion criteria: * age between 19 and 80 years exclusion criteria: * diet containing capsaicin (cayenne pepper, capsicum) (spicy foods), more than once a week. * meal containing capsaicin (spicy foods) within 5 days prior to the experiment. * any lesion, cracking, cold sore or abrasion on the lips * inability to tolerate capsaicin containing "spicy foods" * wearing lipstick or lip balm on the upper lip * inability to fill out an nrs pain scale * use of painkilling medication, within 24 hours of the study. * allergy to any of the ingredients of the creams, or to mannitol * history of contact or allergic dermatitis * pregnant or nursing women

Keywords: mannitol trpv1 receptor pain burning pain neuropathy neuropathic pain
echocardiographic study of a single dose bisoprolol versus nebivolol in healthy subjects

Conditions: Bisoprolol Adverse Reaction; Nebivolol Adverse Reaction

Summary: this is a randomized, double-blind, crossover study in healthy adult subjects. each subject will receive a single dose of bisoprolol 5 mg p.o. and nebivolol 5 mg p.o. with 1 week washout period. all subjects will undergo a physical examination, 12-lead electrocardiography and a comprehensive echocardiographic study before the administration of the study drug and 5 hours thereafter.


Eligibility criteria:
inclusion criteria: 1. healthy subjects (male and female) 2. age interval: 20-60 years old (inclusive) exclusion criteria: 1. any known absolute or relative contraindication to beta-blocker therapy 2. poor echogenicity 3. a resting heart rate \<60 bpm 4. a resting blood pressure \< 110/70 mmhg
efficacy of s-adenosylmethionine in fibromyalgia

Conditions: Fibromyalgia Syndrome

Summary: fundamentally, the trial aims to conduct a gold-standard test of the clinical impact of sam-e in the treatment of depressed mood and general symptoms of fibromyalgia (fms). as such, salient clinical and pathological parameters will be assessed over an 8-week period in 60 patients who will be provided with either sam-e or a placebo preparation . on the basis of previous literature, it is hypothesised that patients in the active treatment group will experience moderate but significant improvements across the clinical measures, and that these gains will be significantly greater than any reported in the placebo group. all patients will provide informed consent. all procedures will be conducted under medical supervision and the preparation itself is very safe when used in the manner proposed for the trial


Eligibility criteria:
inclusion criteria: * diagnosis of fibromyalgia by a medical practitioner exclusion criteria: * pregnancy, manic and hypomanic conditions

Keywords: s-adenosylmethionine
a study to assess the effects of naproxcinod and naproxen on blood pressure measurements in osteoarthritis patients with controlled high blood pressure

Conditions: Osteoarthritis; Hypertension

Summary: to assess the effect of naproxcinod vs. naproxen on arterial blood pressure patients with osteoarthritis and controlled essential hypertension

this is a 12-week, randomized, double-blind, multicenter study comparing the effect of naproxcinod and naproxen on 24 hour arterial blood pressure profile. patients will be randomly allocated to different naproxcinod or naproxen doses in a 1:1 ratio.

Eligibility criteria:
inclusion criteria: * men/women, 40 or older, diagnosed with hip or knee osteoarthritis. * hypertensive patient with treated and controlled essential hypertension. * must receive at least one antihypertensive treatment from the following drug classes: diuretic, angiotensin-converting enzyme (ace) inhibitor, angiotensin receptor blocker (arb) or beta-blocker (bb). * must be current chronic user of nsaids or acetaminophen. * must discontinue all analgesic therapy at screening. exclusion criteria: * more than two different classes of antihypertensive drugs. * uncontrolled diabetes. * hepatic or renal impairment. * a history of alcohol/drug abuse. * diagnosis of gastric or duodenal ulceration and/or history of significant gastro-duodenal bleeding. * history of congestive heart failure. * clinically relevant abnormal ecg. * current or expected use of anticoagulants. * current or history of any medical disease that could interfere with the study objectives or put the patient's safety at risk. * participation within 30 days prior to pre-screening in another investigational study.
assessment of sublingual immunotherapy in children allergic to house dust mites

Conditions: Bronchial Asthma; Allergic Rhinitis

Summary: the purpose of the trial is to asses the efficacy and safety of sublingual annual immunotherapy in children with bronchial asthma and/or allergic rhinitis allergic to house dust mites.

allergen immunotherapy is currently the only one method of cause treatment of the ige-dependent allergic diseases. sublingual immunotherapy (slit) is the method which allows to give allergens via alternative oral route in patients home. due to possibility of avoiding injection this therapy offers better relationship with pediatric patient. however efficacy and safety of sublingual immunotherapy are still important issues, especially in asthmatic children. the purpose of the trial is to asses the efficacy and safety of sublingual annual immunotherapy in children with bronchial asthma and/or allergic rhinitis allergic to house dust mites.

Eligibility criteria:
inclusion criteria: * patients with bronchial asthma and/or allergic rhinitis allergic to house dust mites first diagnosed at least 2 years before the study exclusion criteria: * active respiratory tract infection requiring antibiotic treatment within 4 weeks before the study * hospitalisation due to asthma exacerbation during the 3 months before the first visit * known contraindications of sit according to the eaaci * previous allergen immunotherapy * use of systemic corticosteroids * other clinically significant pulmonary, hematologic, hepatic, gastrointestinal, renal, endocrine, neurologic, cardiovascular, and/or mental diseases or malignancy that either put the patient at risk when participating in the study or could influence the results of the study

Keywords: slit bronchial asthma allergic rhinitis
epidemiology of respiratory insufficiency in critical care

Conditions: Acute Respiratory Failure

Summary: acute respiratory failure is a common entity in intensive care units nowadays and is associated with significant morbidity and mortality, thus representing a major health problem. most of the published epidemiological studies on this condition were performed when modern ventilatory strategies and non-invasive ventilation were not available. therefore, an actual evaluation on the incidence and outcomes of this syndrome is mandatory. we will perform an observational prospective study of patients admitted with acute respiratory insufficiency in several icus in brazil.


Eligibility criteria:
inclusion criteria: * need for non-invasive or invasive mechanical ventilation for more than 24 hours in the first 48 hours of admission to the intensive care unit. exclusion criteria: * tracheostomized patients * patients admitted to icus for monitoring or in post-operatory of non-complicated surgeries. * patients with cancer on terminal stage.

Keywords: acute respiratory failure acute lung injury acute respiratory distress syndrome mechanical ventilation non-invasive ventilation